FY26 Appendix 4E & Audited Financial Report
Filed with ASX · · 60 pages · English
Summary by 6ix AI
The report indicates a significant loss from ordinary activities after tax, reflecting increased costs associated with commercialization efforts. The report outlines the company's transition from development to commercialization, emphasizing achievements in product sales and partnerships.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Response to ASX Query Letter
- First ColoSTAT Clinical Test Sale
- NATA Accredits ColoSTAT Clinical Testing Service
- RHY Executes SE Asian Genetype Distribution Agreement
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
Later from Rhythm Biosciences
- Initial ColoSTAT Assessment in UK opens new market access
- ColoSTAT Economic Study - Australian Public Health Savings
- Quarterly Activities Report and Appendix 4C
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences